diaDexus Inc

Type: Company
Name: diaDexus Inc
First reported Aug 18 2014 - Updated Aug 18 2014 - 2 reports

diaDexus, Inc. Secures $15 Million Debt Financing

. (OTCQB:DDXS), a commercial stage developer of proprietary cardiovascular diagnostic products, today announced it has entered into a $15 million senior secured term loan with Oxford Finance. The Company will use the funding to refinance its existing ... [Published Pettinga Financial Advisors - Aug 18 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 3 reports

diaDexus Price Target Cut to $1.75 (DDXS)

Equities research analysts at Maxim Group dropped their target price on shares of diaDexus (NASDAQ:DDXS)Separately, analysts at Zacks downgraded shares of diaDexus from a “hold” rating to a “sell” rating in a research note on Tuesday, May 13th.diaDexus ... [Published American Banking News - Stock Ratings - Jul 29 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 3 reports

diaDexus, Inc. to Host Conference Call and Webcast July 28, 2014 to Discuss Second Quarter 2014 Financial Results

diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it will host a conference call and webcast on Monday, July 28, 2014 at 4:30 PM ET (1:30 PM PT) to discuss its 2014 ... [Published Stock Nod - Jul 21 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 1 reports

2nd Quarter Executive Turnover Remains Positive - Investment Ops Abound

Executive turnover continues in a positive direction despite a slowdown in a few of the key categories.  The trend in executive turnover continues to correlate with the continuing positive news related to job growth in the American economy and the declining ... [Published Management Turnover as Change Agent - Jul 17 2014]
First reported Jul 17 2014 - Updated Jul 17 2014 - 5 reports

diaDexus Announces FDA Acceptance for Review of 510(k) Submission for PLAC Test for Lp-PLA2 Activity

. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that an administrative acceptance review was conducted ... [Published Pettinga Financial Advisors - Jul 17 2014]
First reported Jun 25 2014 - Updated Jun 25 2014 - 1 reports

diaDexus Announces Leadership Changes to Drive and Support Future Growth Potential

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced leadership changes designed to expedite execution of the company’s diversification ... [Published Business Wire Health News - Jun 25 2014]
First reported May 15 2014 - Updated May 15 2014 - 1 reports

diaDexus to Present at the Jefferies 2014 Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that Brian E. Ward, Ph.D., president and chief executive officer, is scheduled ... [Published Business Wire Health News - May 15 2014]
First reported May 07 2014 - Updated May 07 2014 - 1 reports

diaDexus, Inc. Reports First Quarter 2014 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the first quarter ended March 31, 2014. "In the ... [Published Business Wire Health News - May 07 2014]
First reported May 01 2014 - Updated May 01 2014 - 1 reports

diaDexus Announces Completion of Validation Cohort for the PLAC® Test for Lp-PLA2 Activity

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced completion of the validation study that it will use to support submission ... [Published Business Wire Health News - May 01 2014]
First reported Apr 29 2014 - Updated Apr 30 2014 - 1 reports

diaDexus, Inc. to Host Conference Call and Webcast May 7, 2014 to Discuss First Quarter 2014 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it will host a conference call and webcast on Wednesday, May 7, 2014 ... [Published Business Wire Health News - Apr 29 2014]
First reported Mar 05 2014 - Updated Mar 06 2014 - 1 reports

diaDexus, Inc. Reports Fourth Quarter and Full Year 2013 Financial Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the fourth quarter and full year ended December ... [Published Business Wire Health News - Mar 05 2014]
First reported Mar 05 2014 - Updated Mar 05 2014 - 1 reports

diaDexus, Inc. Announces Exclusive U.S. Licensing Deal with Thermo Fisher Scientific to Advance Risk Prediction in Heart Failure

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced an exclusive licensing and supply agreement with Thermo Fisher Scientific ... [Published Business Wire Health News - Mar 05 2014]

Quotes

"We are pleased to have secured this financing from Oxford,” said Lori Rafield, Ph D , interim executive chair and chairman of the board for diaDexus. “This loan solidifies our balance sheet and provides the growth capital needed to diversify our portfolio, expand our customer base and support the needs of our established customers. We now have the foundation in place to enable future growth by maximizing sales and marketing efforts directed at our anticipated U S launch of the PLAC® Test for Lp-PLA2"
...1 million debt from Comerica and advance the company’s development and commercialization of additional diagnostic testing solutions. "We are pleased to have secured this financing from O"
...and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the second quarter ended June 30, 2014. "We had a strong second quarter with 23 percent growth in our year-over-year revenue, including a significant contribution coming from our services agreement with GlaxoSmithKline GSK) in addition to 7 percent growth in our base PLAC mass assay business,” said Lori Rafield, Ph D , interim executive chair and chairman of the board for diaDexus. “As the marketplace begins to change with new industry-wide regulatory guidelines and potential competitive products, we remain focused on diversification of our portfolio, expansion of our customer base and continued support of our established customers. The continued evolution of the company’s leadership team announced last month will support these efforts and our future growth.” Recent Highlights"
...and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the second quarter ended June 30, 2014. "We had a strong second quarter with 23 percent growth in our year-over-year revenue, including a significant contribution coming from our services agreement with GlaxoSmithKline GSK) in addition to 7 percent growth in our base PLAC mass assay business,”"

More Content

All (22) | News (7) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
diaDexus, Inc. Secures $15 Million Debt Financing [Published Pettinga Financial Advisors - Aug 18 2014]
diaDexus, Inc. Secures $15 Million Debt Financing [Published Business Wire Health News - Aug 18 2014]
diaDexus Price Target Cut to $1.75 (DDXS) [Published American Banking News - Stock Ratings - Jul 29 2014]
diaDexus, Inc. Reports Second Quarter 2014 Fina... [Published Investor's Business Daily - Jul 28 2014]
diaDexus, Inc. Reports Second Quarter 2014 Fina... [Published Business Wire Health News - Jul 28 2014]
diaDexus, Inc. to Host Conference Call and Webc... [Published Stock Nod - Jul 21 2014]
diaDexus, Inc. to Host Conference Call and Webc... [Published Digital Journal - Jul 21 2014]
diaDexus, Inc. to Host Conference Call and Webc... [Published Business Wire Health News - Jul 21 2014]
2nd Quarter Executive Turnover Remains Positive... [Published Management Turnover as Change Agent - Jul 17 2014]
diaDexus Announces FDA Acceptance for Review of... [Published Pettinga Financial Advisors - Jul 17 2014]
diaDexus Announces FDA Acceptance for Review of... [Published Scottrade - Jul 17 2014]
diaDexus Announces FDA Acceptance for Review of... [Published EON Science - Jul 17 2014]
diaDexus Announces FDA Acceptance for Review of... [Published Business Wire Science: Science News - Jul 17 2014]
diaDexus Announces FDA Acceptance for Review of... [Published Business Wire Health News - Jul 17 2014]
diaDexus Announces Leadership Changes to Drive ... [Published Business Wire Health News - Jun 25 2014]
diaDexus to Present at the Jefferies 2014 Globa... [Published Business Wire Health News - May 15 2014]
diaDexus, Inc. Reports First Quarter 2014 Finan... [Published Business Wire Health News - May 07 2014]
diaDexus Announces Completion of Validation Coh... [Published Business Wire Health News - May 01 2014]
diaDexus, Inc. to Host Conference Call and Webc... [Published Business Wire Health News - Apr 29 2014]
diaDexus, Inc. Reports Fourth Quarter and Full ... [Published Business Wire Health News - Mar 05 2014]
diaDexus, Inc. Announces Exclusive U.S. Licensi... [Published Business Wire Health News - Mar 05 2014]
diaDexus, Inc. to Host Conference Call and Webc... [Published Business Wire Health News - Feb 19 2014]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
diaDexus, Inc. Secures $15 Million Debt Financing [Published Business Wire Health News - Aug 18 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB:DDXS), a commercial stage developer of proprietary cardiovascular diagnostic products, today announced it has entered into a $15 million senior secured term loan with Oxford Finance. ...
diaDexus, Inc. Reports Second Quarter 2014 Fina... [Published Business Wire Health News - Jul 28 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB: DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the second quarter ended June 30, 2014. "We had ...
diaDexus, Inc. to Host Conference Call and Webc... [Published Business Wire Health News - Jul 21 2014]
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it will host a conference call and webcast on Monday, July 28, 2014 ...
2nd Quarter Executive Turnover Remains Positive... [Published Management Turnover as Change Agent - Jul 17 2014]
Executive turnover continues in a positive direction despite a slowdown in a few of the key categories.  The trend in executive turnover continues to correlate with the continuing positive news related to job growth in the American economy and the declining ...
diaDexus Announces FDA Acceptance for Review of... [Published EON Science - Jul 17 2014]
SOUTH SAN FRANCISCO, Calif.--(EON: Enhanced Online News)--diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that it has received notice from the U.S. Food and Drug Administration ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.